SAN DIEGO, July 6, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the second quarter 2018 on Tues., Aug. 7 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the
second quarter ended June 30, 2018 following the close of trading.
The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made
available following the close of the call. To access the webcast and additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately fifteen
minutes prior to the call to register, download and install any necessary audio software. The live call may be accessed by
dialing (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay
will be available after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using
replay ID number 40189200.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies
that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique
approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer,
metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In
addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE®
drug delivery technology. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-second-quarter-2018-financial-results-conference-call-300676648.html
SOURCE Halozyme Therapeutics, Inc.